This page provides an overview of the investment and market landscape for neurodegenerative disease therapeutics. The neurodegenerative disease therapeutics market represents one of the largest unmet medical needs in healthcare, with significant investment flowing into research and development across Alzheimer's disease, Parkinson's disease, ALS, and related conditions.
| Disease |
Market Size |
Growth Rate |
| Alzheimer's |
$6.5B |
12% annually |
| Parkinson's |
$5.5B |
10% annually |
| ALS |
$1.2B |
8% annually |
| Other |
$2B |
7% annually |
| Disease |
Projected Size |
CAGR |
| Alzheimer's |
$25B+ |
15% |
| Parkinson's |
$15B+ |
12% |
| ALS |
$3B+ |
10% |
| Total |
$50B+ |
13% |
| Year |
Deals |
Total Value |
Avg Deal Size |
| 2020 |
45 |
$3.2B |
$71M |
| 2021 |
62 |
$5.8B |
$94M |
| 2022 |
55 |
$4.5B |
$82M |
| 2023 |
48 |
$3.8B |
$79M |
| 2024 |
52 |
$4.2B |
$81M |
| Disease |
2024 Investment |
Share |
| Alzheimer's |
$2.1B |
50% |
| Parkinson's |
$1.2B |
29% |
| ALS |
$0.5B |
12% |
| Other |
$0.4B |
9% |
The neurodegenerative disease pipeline remains heavily weighted toward early-stage programs, reflecting the high-risk nature of CNS drug development:
- Preclinical: ~400 programs
- Phase I: ~120 programs
- Phase II: ~80 programs
- Phase III: ~25 programs
| Modality |
Percentage |
Key Examples |
| Small Molecule |
45% |
AChE inhibitors, MAO-B inhibitors |
| Biologics |
30% |
Monoclonal antibodies, peptides |
| Gene Therapy |
15% |
AAV vectors, CRISPR approaches |
| Cell Therapy |
10% |
Stem cell replacements |
The majority of pipeline programs focus on well-established targets:
- Amyloid-beta (Aβ): 25+ programs
- Tau: 20+ programs
- Alpha-synuclein: 15+ programs
- Neuroinflammation (TREM2, complement): 18+ programs
- Neuroprotection (BDNF, growth factors): 12+ programs
| Company |
Deals 2024 |
Focus |
| Eli Lilly |
5 |
Alzheimer's |
| Biogen |
4 |
Alzheimer's |
| Roche |
3 |
Alzheimer's, Parkinson's |
| AbbVie |
3 |
Parkinson's |
| Firm |
Portfolio Cos |
Stage Focus |
| ARCH Venture |
8 |
Early |
| Third Rock |
6 |
Early-mid |
| Andreessen Horowitz |
5 |
Early |
| GV |
4 |
Early |
¶ Risk Factors and Challenges
Neurodegenerative disease drug development faces unique challenges:
- Long trial durations: Phase III trials often require 18-24 months of patient follow-up
- Patient recruitment: Slow enrollment due to diagnostic uncertainty and competition across trials
- Biomarker validation: Limited validated biomarkers for patient stratification and endpoint measurement
- Placebo response: High placebo response rates complicate signal detection
- FDA has granted Breakthrough Therapy designation to 15+ programs
- Accelerated approval pathway used for amyloid-targeting antibodies
- Real-world evidence increasingly accepted for regulatory decisions
| Region |
2024 Investment |
Share |
| United States |
$2.5B |
60% |
| Europe |
$0.8B |
19% |
| China |
$0.5B |
12% |
| Japan |
$0.2B |
5% |
| Other |
$0.2B |
4% |
- Boston/Cambridge: Highest concentration of neurodegenerative research
- San Francisco Bay Area: Strong biotech ecosystem with academic partnerships
- UK (Oxford/Cambridge): Academic translation and biotech spinouts
- China: Growing investment in CNS pipeline, particularly generics-to-innovation
¶ Exit Landscape
| Company |
Date |
Valuation |
Disease |
| Prothelia |
2024 |
$500M |
Alzheimer's |
| Clene |
2023 |
$200M |
ALS |
| Acurex |
2023 |
$150M |
Parkinson's |
| Acquirer |
Target |
Year |
Value |
| Eli Lilly |
Dice |
2024 |
$2.4B |
| Biogen |
Reata |
2023 |
$6.5B |
- Aging demographics: Global population aging ensures continued disease burden
- Diagnostic advances: Earlier detection enables preventive interventions
- Precision medicine: Biomarker-driven patient selection improving trial success
- Novel modalities: Gene therapy and cell therapy platforms maturing
By 2035, the neurodegenerative disease therapeutics market is projected to reach $80-100B, driven by:
- Approval of disease-modifying therapies for Alzheimer's
- Expansion of Parkinson's pipeline
- Emerging gene and cell therapy approvals
- Geographic market expansion